Brookline raised the firm’s price target on IceCure Medical (ICCM) to $4.60 from $4.16 and keeps a Buy rating on the shares after Q3 results the firm calls “as expected” and the FDA AdComm vote earlier this month in favor of approving ProSense for treatment of low-risk breast cancer. The firm expects approval in Q1 of 2025, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure Medical’s Promising Growth and FDA Anticipation
- IceCure Medical reports 36% sales growth in first nine months of 2024
- IceCure Medical’s Cryoablation Innovation Gains Momentum
- IceCure Medical receives Notice of Allowance from Japan’s Patent Office
- ICCM Earnings this Week: How Will it Perform?
Questions or Comments about the article? Write to editor@tipranks.com